Search

Your search keyword '"Kristine Pek Ling Ng"' showing total 6 results
Start Over Author "Kristine Pek Ling Ng"
6 results on '"Kristine Pek Ling Ng"'

1. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

Author

Rangi Kandane-Rathnayake, Worawit Louthrenoo, Alberta Hoi, Shue-Fen Luo, Yeong-Jian J. Wu, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Sandra V. Navarra, Leonid Zamora, Sargunan Sockalingam, Yuan An, Zhanguo Li, Yasuhiro Katsumata, Masayoshi Harigai, Yanjie Hao, Zhuoli Zhang, Jun Kikuchi, Tsutomu Takeuchi, B. M. D. B. Basnayake, Madelynn Chan, Kristine Pek Ling Ng, Nicola Tugnet, Sunil Kumar, Shereen Oon, Fiona Goldblatt, Sean O’Neill, Kathryn A. Gibson, Naoaki Ohkubo, Yoshiya Tanaka, Sang-Cheol Bae, Chak Sing Lau, Mandana Nikpour, Vera Golder, Eric F. Morand, and For the Asia-Pacific Lupus Collaboration

Subjects
Systemic lupus erythematosus, Disease activity, Outcomes, Quality of life, Unmet need, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], p

Published
2022
Full Text
View/download PDF

2. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study

Author

Kathryn Connelly, Rangi Kandane-Rathnayake, Alberta Hoi, Worawit Louthrenoo, Laniyati Hamijoyo, Jiacai Cho, Aisha Lateef, Shue Fen Luo, Yeong-Jian J Wu, Zhanguo Li, Sandra Navarra, Leonid Zamora, Sargunan Sockalingam, Yanjie Hao, Zhuoli Zhang, Yasuhiro Katsumata, Masayoshi Harigai, Shereen Oon, Madelynn Chan, Yi-Hsing Chen, Sang-Cheol Bae, Sean O'Neill, Fiona Goldblatt, Jun Kikuchi, Tsutomu Takeuchi, Kristine Pek Ling Ng, Nicola Tugnet, B M D B Basnayake, Naoaki Ohkubo, Yoshiya Tanaka, Chak Sing Lau, Mandana Nikpour, Vera Golder, and Eric F Morand

Subjects
Rheumatology, Immunology, Immunology and Allergy
Published
2022
Full Text
View/download PDF

3. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study

Author

Rangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, Yeong-Jian J Wu, Sandra V Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Yanjie Hao, Zhuoli Zhang, B M D B Basnayake, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang-Cheol Bae, Shereen Oon, Sean O'Neill, Fiona Goldblatt, Kristine Pek Ling Ng, Annie Law, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, DaeYoung Yu, Chetan S Karyekar, Chak Sing Lau, Julie A Monk, Mandana Nikpour, Alberta Hoi, and Eric F Morand

Subjects
Rheumatology, Immunology, Immunology and Allergy
Published
2022
Full Text
View/download PDF

4. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study

Author

Kathryn Connelly, Rangi Kandane‐Rathnayake, Alberta Hoi, Worawit Louthrenoo, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Jiacai Cho, Aisha Lateef, CS Lau, Yi‐Hsing Chen, Sandra Navarra, Leonid Zamora, Zhanguo Li, Yuan An, Sargunan Sockalingam, Yanjie Hao, Zhuoli Zhang, Madelynn Chan, Yasuhiro Katsumata, Masayoshi Harigai, Shereen Oon, Sang‐Cheol Bae, Sean O'Neill, Kathryn A. Gibson, BMDB Basnayake, Jun Kikuchi, Tsutomu Takeuchi, Kristine Pek Ling Ng, Nicola Tugnet, Sunil Kumar, Fiona Goldblatt, Annie Law, Michael Tee, Cherica Tee, Yoshiya Tanaka, Naoaki Ohkubo, Jin Yu Tan, Chetan S. Karyekar, Mandana Nikpour, Vera Golder, and Eric F. Morand

Subjects
Rheumatology, Immunology, Immunology and Allergy
Abstract

In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long-term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up to 5 years of follow-up.We used data from a large multicenter, longitudinal SLE cohort in which patients received standard of care. The first visit with active disease (defined as SLE Disease Activity Index 2000 [SLEDAI-2K] score ≥6) was designated as baseline, and mSRI attainment (defined as a reduction in SLEDAI-2K ≥4 points with no worsening in physician global assessment ≥0.3 points) was determined at annual intervals from baseline up to 5 years. Associations between mSRI attainment and outcomes including disease activity, glucocorticoid dose, flare, damage accrual, Lupus Low Disease Activity State (LLDAS), and remission were studied.We included 2,060 patients, with a median baseline SLEDAI-2K score of 8. An mSRI response was attained by 56% of patients at 1 year, with similar responder rates seen at subsequent annual time points. Compared to nonresponders, mSRI responders had significantly lower disease activity and prednisolone dose and higher proportions of LLDAS and remission attainment at each year, and less damage accrual at years 2 and 3. Furthermore, mSRI responder status at 1 year predicted clinical benefit at subsequent years across most outcomes, including damage accrual (odds ratio [OR] range 0.58-0.69, P 0.05 for damage accrual ORs at all time points).In SLE patients with active disease receiving standard of care, mSRI attainment predicts favorable outcomes over long-term follow-up, supporting the clinical meaningfulness of SRI attainment as an SLE trial end point.

Published
2022

6. LSO-087 Sub-optimal use of anti-malarial therapy for SLE in the Asia Pacific region; observations from the Asia Pacific lupus cohort

Author

Tsutomu Takeuchi, Yoshiya Tanaka, Rangi Kandane-Rathnayake, Sang-Cheol Bae, Zhanguo Li, Shereen Oon, Vera Golder, Mandana Nikpour, Masayoshi Harigai, Yi-Hsing Chen, Zhuoli Zhang, Eric Morand, Chak Sing Lau, Sunil Kumar, Alberta Hoi, Sandra Navarra, Sean O’Neill, Michael Tee, Jun Kikuchi, Yanjie Hao, Shue Fen Luo, Yasuhiro Katsumata, Aisha Lateef, Laniyati Hamijoyo, Sargunan Sockalingam, Nicola Tugnet, Madelynn Chan, Jiacai Cho, Cherica Tee, Leonid Zamora, BMDB Basnayake, Fiona Goldblatt, Naoaki Ohkubo, Kristine (Pek Ling) Ng, Louthrenoo Worawit, Yeong-Jian Jan Wu, and Annie Hui Nee Law

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results